Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 966-972
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.966
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.966
Study | Concurrent chemotherapy | Radiation | Notes |
Tax 323 | None | Conventional (66 to 70 Gy), accelerated (70 Gy) or hyperfractionated (74 Gy) | Only study not to use concurrent chemotherapy |
Tax 324 | Carboplatin AUC 1.5, weekly | Radiation 2 Gy per day, 5 d a week for a total of 70-74 Gy | |
PARADIGM: responders | Carboplatin AUC 1.5, weekly | 70 Gy over 7 wk | Regimen varied by response to induction |
PARADIGM: non-responders | Docetaxel 20 mg/m2 weekly | Accelerated concomitant boost over 6 wk (72 Gy) | Regimen varied by response to induction |
DeCIDE | CRT: five 14 d cycles of docetaxel (day 1), fluorouracil (day 0-4) and hydroxyurea (day 0-4) | Twice daily radiation (day 1-5) | Split course radiation |
- Citation: Georges P, Rajagopalan K, Leon C, Singh P, Ahmad N, Nader K, Kubicek GJ. Chemotherapy advances in locally advanced head and neck cancer. World J Clin Oncol 2014; 5(5): 966-972
- URL: https://www.wjgnet.com/2218-4333/full/v5/i5/966.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i5.966